We are very happy to attend to the 15th World Bispecific Summit 2024 of Boston, organized by Hanson Wade.
The 15th World Bispecific Summit 2024 is the industry-focused meeting that brings together the leading pharma, biotech and academic leaders at the forefront of bi, tri and multi-specific development to harness the full potential of bispecific antibodies.
Moving towards more personalized medicine, profiling bispecific candidates preclinically to ensure the developability has never been more important. This summit is focused on the radically optimize Bi, Tri & Multispecific Antibodies to enhance Target discovery, Mechanistic diversity and Clinical translation to maximize the Therapeutic Index and Enhance combinations. Among numerous innovations in cancer immunotherapy, one of the most promising has been the development of bispecific drugs, with constant clinical updates and approvals over the last year.
As of 2023, more than 10 bispecific antibodies have been successfully approved by the FDA, and more than 100 are currently in clinical trials, highlighting biopharma’s continued investment within bispecific therapeutics. Given the reach bispecific drugs can have, the hunt is on for novel targets that can transform the lives of patients, whether it’s new targets and combinations to improve the safety profile for haematological malignancies, overcoming the immunosuppressive microenvironment within solid tumors, or switching the immune system off in autoimmune disease.
Save the Date!!! Next Wednesday, 4th of September, Giorgio Salciarini our Technical Business Development Senior Manager, Head of Sales, will present its speech 'Meeting envolving needs in Oncology and Immunotherapy' during the Conference Day 1, from 14:00 PM.
BSP's team looks forward to meeting You at our booth in the Exhibitors Area To request a meeting, please send an e-mail to Business.Development@Bsppharmaceuticals.com
